In light of recent wins for mRNA vaccine makers, UCSC RNA Center Co-Director Jeremy Sanford describes the versatility of the ...

As flu season approaches, local health officials are urging older adults to look into a newly approved, highly effective ...

Moderna’s vaccine, intismeran, is a personalized neoantigen vaccine. It delivers mRNA that encodes tumor-specific mutations ...

Study of an experimental alternative to the industry standard suggests therapeutics could be delivered faster and more ...

Vaccines have been reliably and affordably protecting people from diseases worldwide for centuries. Until the COVID-19 ...

New research by Malaghan's Connor Laboratory, published in PNAS, shows how directing the immune system toward conserved areas ...

For patients with diseases caused by certain genetic mutations, tRNA therapy – though still in the experimental stages – ...

Researchers at Nagoya University in Japan in collaboration with FUJIFILM have developed a novel way of delivering circular ...

While mRNA may be back in the headlines courtesy of Moderna and Merck & Co.'s phase 3 cancer vaccine success, new research ...

Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Moderna (NASDAQ:MRNA) and its peers.

Expanding oncology and rare disease pipelines, strategic partnerships, and advances in delivery technologies are expected to drive significant market growthDublin, Aug. (GLOBE NEWSWIRE) -- The "mRNA ...

A new study from researchers at the Texas A&M College of Veterinary Medicine and Biomedical Sciences (VMBS) has uncovered a ...